Moreover, using human pulmonary microvascular ECs and two conventional rat PAH models with either chronic hypoxia or monocrotaline treatment, Reynolds and co-workers showed that targeted adenoviral BMPR2 gene delivery displays success in attenuation of PAH properties (Reynolds et al., 2007, 2012). The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.